CCO
BioDuro-Sundia Appoints Alan Findlater as Chief Commercial Officer to Drive Strategic Growth and Enhance Market Position
BioDuro-Sundia
PR-12-24-NI-123Dec 03, 2024
M&A
Olon Continues its Growth Path and Announces a New Acquistion
Olon
PR-09-24-NI-01Sep 04, 2024
New Biomanufacturing Facility
Samsung Biologics Announces Construction of Plant 5 to Commence Bio Campus II Capacity Expansion
Samsung Biologics
PR-M03-23-05Mar 17, 2023
Life Science Industrials
Life Science Industrials Are Key to the Growth of the Biopharma Industry
Reinhard Vogt
Dynamk Capital
PAO-07-022-CL-05Aug 04, 2022
Site Expansion
Vetter’s Newest Clinical Manufacturing Site Successfully Completed Its First Customer Fills
Vetter Pharma International GmbH
PR-M06-22-07Jun 28, 2022
R&D
Driving Further Innovation by Integrating a Decentralized R&D Network
Giorgio Bertolini, Ph.D.
Olon
PAO-06-022-CL-02Jun 01, 2022
M&A
Growing a Forward-Thinking CDMO
CoreRx
PAO-04-22-R250-78May 04, 2022
Facility Expansion
Alcami Expands Biopharma Storage at Masy BioServices
Alcami
PR-M03-22-15Mar 29, 2022
Investment
Global Investment Trends and Getting Noticed by PE/VC Firms
Iesan Tsai
Kiri Capital
PAO-02-022-CL-15Mar 15, 2022
Consulting
Helping Biopharma Companies Grow with Insight
Philip Gialenios
Kineticos Life Sciences
PAO-01-22-R250-17Jan 31, 2022
Strategic Growth
Unique Commercial Experience Primes Avid Bioservices for Growth
Nicholas Green
Avid Bioservices
PAO-05-21-CL-03May 12, 2021
The Future of Healthcare
How Does TriRx Envision the Future of the Pharma/Biopharma Industry?
TriRx Pharmaceutical Services
PAP-Q4-20-RT2-004Dec 09, 2020
The Future of Healthcare
How Is TriRx Pharmaceutical Services Evolving its Business Model to Meet the Future of Healthcare?
TriRx Pharmaceutical Services
PAP-Q3-20-RT2-006Sep 29, 2020
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
Arranta Bio
PAP-Q3-20-RT2-009Sep 29, 2020
Investment
Investing at the Intersection of Industrial Manufacturing and Healthcare
David Q. Anderson
Ampersand Capital Partners
PAP-Q2-20-CL-025Jul 01, 2020